Should I buy or sell AbbVie stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares. View ABBV analyst ratings or view top-rated stocks .

What is AbbVie's stock price target for 2024?

13 brokers have issued 12 month price objectives for AbbVie's stock. Their ABBV share price targets range from $150.00 to $196.00. On average, they anticipate the company's share price to reach $177.43 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts .

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 at the beginning of the year. Since then, ABBV stock has increased by 7.2% and is now trading at $166.13. View the best growth stocks for 2024 here .

Are investors shorting AbbVie?

AbbVie saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 13,120,000 shares, a drop of 10.7% from the March 15th total of 14,690,000 shares. Based on an average daily trading volume, of 5,660,000 shares, the days-to-cover ratio is presently 2.3 days. View AbbVie's Short Interest .

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024. View our ABBV earnings forecast .

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) issued its earnings results on Friday, February, 2nd. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.03. The business earned $14.30 billion during the quarter, compared to the consensus estimate of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 162.28% and a net margin of 8.95%. The firm's revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.60 earnings per share. Read the conference call transcript .

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Monday, April 15th will be given a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date is Friday, April 12th. Read our dividend analysis for ABBV .

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.81%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 50.90% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ABBV .

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include Harbor Health Care ETF (MEDI) , First Trust Morningstar Dividend Leaders Index (FDL) , Horizon Kinetics Medical ETF (MEDX) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Invesco Pharmaceuticals ETF (PJP) , Health Care Select Sector SPDR Fund (XLV) , iShares U.S. Healthcare ETF (IYH) and VanEck Pharmaceutical ETF (PPH) .

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY 2024 earnings guidance on Wednesday, April, 3rd. The company provided earnings per share (EPS) guidance of 10.970-11.170 for the period, compared to the consensus estimate of 11.190. The company issued revenue guidance of -.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com . Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC) , Constellation Software (CSU) , AutoCanada (ACQ) , Alimentation Couche-Tard (ATD.B) , Vermilion Energy (VET) , AT&T (T) , Bristol-Myers Squibb (BMY) , Wheaton Precious Metals (WPM) , Rogers Communications (RCI) and Open Text (OTEX) .

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Guinness Asset Management LTD (0.07%), Global Assets Advisory LLC (0.05%), Ferguson Wellman Capital Management Inc. (0.04%), Miller Howard Investments Inc. NY (0.03%), Artemis Investment Management LLP (0.03%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Azita Saleki-Gerhardt , Brian L Durkin , Carrie C Strom, Carrie C Strom , Elaine K Sorg , Henry O Gosebruch , Jeffrey Ryan Stewart , Kevin K Buckbee, Laura J Schumacher , Michael Severino , Nicholas Donoghoe , Perry C Siatis , Richard A Gonzalez , Robert A Michael , Roxanne S Austin , Scott T Reents and Timothy J Richmond . View institutional ownership trends .

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. Read More

Followed 120 TimesTop Followed Top-Rated Dividend StocksTop-Rated Dividend

NYSE:ABBV

AbbVie (ABBV) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ABBV Stock Alerts

$164.95

+0.70 (+0.43%)

(As of 02:40 PM ET)

Compare

Today's Range: $164.43
▼
$167.44
50-Day Range: $161.67
▼
$182.10
52-Week Range: $130.96
▼
$182.89

Volume: 2.62 million shs
Average Volume: 5.61 million shs
Market Capitalization: $292.07 billion

P/E Ratio: 60.42
Dividend Yield: 3.76%
Price Target: $177.43

Get AbbVie alerts:

AbbVie MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.77 Rating Score
Upside/Downside: 6.8% Upside
$177.43 Price Target
Short Interest: Healthy
0.74% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.34
Upright™ Environmental Score
News Sentiment: 0.34
Based on 53 Articles This Week
Insider Trading: Selling Shares
$67.78 M Sold Last Quarter
Proj. Earnings Growth: 9.04%
From $11.17 to $12.18 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.91 out of 5 stars

Medical Sector

22nd out of 914 stocks

Pharmaceutical Preparations Industry

5th out of 421 stocks

2.4

Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
AbbVie has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.74% of the outstanding shares of AbbVie have been sold short.
Short Interest Ratio / Days to Cover
AbbVie has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AbbVie has recently decreased by 10.69%, indicating that investor sentiment is improving significantly.

4.2

Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 3.81%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 52 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 50.90% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AbbVie has received a 52.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Adalimumab", "Ibrutinib", and "Hepatitis medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AbbVie is -2.34.

3.0

News and Social Media Coverage

News Sentiment
AbbVie has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 53 news articles for AbbVie this week, compared to 22 articles on an average week.
Search Interest
173 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.
MarketBeat Follows
119 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,780,003.00 in company stock.
Percentage Held by Insiders
Only 0.25% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to grow by 9.04% in the coming year, from $11.17 to $12.18 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 60.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.99.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 60.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 187.06.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 2.09. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AbbVie has a P/B Ratio of 28.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad GoldenCrest Metals

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABBV Stock News Headlines

March 24, 2024 | marketbeat.com

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (ABBV)

Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.

March 23, 2024 | insidertrades.com

AbbVie Inc. (NYSE:ABBV) EVP Sells $3,716,756.60 in Stock

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

March 21, 2024 | insidertrades.com

Insider Selling: AbbVie Inc. (NYSE:ABBV) EVP Sells 58,949 Shares of Stock

April 18, 2024 | marketwatch.com

AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint

April 18, 2024 | msn.com

AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition

April 18, 2024 | markets.businessinsider.com

AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis

April 18, 2024 | finance.yahoo.com

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

April 18, 2024 | prnewswire.com

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

April 18, 2024 | reuters.com

US FDA warns of harmful reactions to fake Botox injections

April 17, 2024 | msn.com

CVS favors Humira copycats hurting AbbVie’s market share: Evercore

April 17, 2024 | 247wallst.com

Want $2000 In Passive Income? Invest $1000 Into These Dividend Stocks

April 16, 2024 | msn.com

Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally

April 16, 2024 | seekingalpha.com

AbbVie: Through Humira's Crisis Towards Solid Growth

April 16, 2024 | marketwatch.com

Medincell, AbbVie to Co-Develop Injectable Therapeutics

April 16, 2024 | msn.com

AbbVie working with FDA after reports of fake Botox versions

April 16, 2024 | finance.yahoo.com

UPDATE 1-US FDA warns of harmful reactions to fake Botox injections

April 16, 2024 | investorplace.com

Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now

April 16, 2024 | businesswire.com

Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

April 16, 2024 | businesswire.com

Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

April 16, 2024 | tmcnet.com

QuantHealth Appoints Esteemed Pharmaceutical Executives to Inaugural Advisory Board

April 16, 2024 | msn.com

Humira biosimilar scripts take off

April 15, 2024 | msn.com

AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share

April 15, 2024 | americanbankingnews.com

AbbVie Inc. (NYSE:ABBV) Short Interest Update

April 14, 2024 | seekingalpha.com

AbbVie: Great To Be Proven Wrong - Still Not A Buy

April 14, 2024 | americanbankingnews.com

AbbVie (NYSE:ABBV) Stock Price Down 2.3%

See More Headlines

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend: 1/12/2024
Last Earnings: 2/02/2024
Dividend Payable: 2/15/2024
Ex-Dividend for 5/15 Dividend: 4/12/2024
Today: 4/18/2024
Next Earnings (Confirmed): 4/26/2024
Dividend Payable: 5/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ABBV
CUSIP: 00287Y10
CIK: 1551152
Web: www.abbvie.com
Phone: (847) 932-7900
Fax: 302-655-5049
Employees: 50,000
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $177.43
High Stock Price Target: $196.00
Low Stock Price Target: $150.00
Potential Upside/Downside: +7.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.77
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.73
Trailing P/E Ratio: 60.52
Forward P/E Ratio: 14.79
P/E Growth: 2.09
Net Income: $4.86 billion
Net Margins: 8.95%
Pretax Margin: 11.51%
Return on Equity: 162.28%
Return on Assets: 14.62%

Debt

Debt-to-Equity Ratio: 5.02
Current Ratio: 0.87
Quick Ratio: 0.76

Sales & Book Value

Annual Sales: $54.32 billion
Price / Sales: 5.39
Cash Flow: $16.07 per share
Price / Cash Flow: 10.28
Book Value: $5.78 per share
Price / Book: 28.59

Miscellaneous

Outstanding Shares: 1,770,650,000
Free Float: 1,766,220,000
Market Cap: $292.56 billion
Optionable: Optionable
Beta: 0.58

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Richard A. Gonzalez (Age 70)
Chairman & CEO
Comp: $7.19M
Mr. Robert A. Michael (Age 54)
President & COO
Comp: $4.62M
Mr. Scott T. Reents (Age 56)
Executive VP & CFO
Comp: $3.13M
Dr. Azita Saleki-Gerhardt Ph.D. (Age 61)
Executive VP & COO
Comp: $3.51M
Mr. Jeffrey Ryan Stewart (Age 55)
Executive VP & Chief Commercial Officer
Comp: $4.32M
Dr. Thomas J. Hudson M.D. (Age 62)
Senior VP & Chief Scientific Officer of Global Research
Ms. Elizabeth Shea
Senior Vice President of Investor Relations
Mr. Perry C. Siatis (Age 49)
Executive VP, General Counsel & Secretary
Mr. Sanjay Narayan
Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Timothy J. Richmond (Age 58)
Executive VP & Chief Human Resources Officer
Comp: $1.12M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie offers a diverse range of pharmaceutical products, including innovative treatments like Skyrizi and Rinvoq, which have shown promising results in treating various diseases.
The company has a strong pipeline of drugs in development, indicating potential for future growth and revenue generation.
AbbVie's collaboration with reputable companies like Janssen Biotech and Genentech for developing biologics showcases its commitment to innovation and expanding its product portfolio.
Recent positive developments in AbbVie's financial performance, coupled with a stable dividend payout, make it an attractive option for income-seeking investors.
Considering the current stock price and market trends, AbbVie's stock shows potential for capital appreciation in the near future.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

AbbVie faces risks associated with patent expirations of key drugs, which could lead to revenue declines and increased competition from generic alternatives.
The pharmaceutical industry is highly regulated, and any changes in regulations or unexpected legal challenges could impact AbbVie's operations and financial performance.
Concerns about the potential impact of healthcare reforms or changes in reimbursement policies on AbbVie's profitability may pose risks to investors.
Market volatility and macroeconomic factors could affect AbbVie's stock price, leading to fluctuations in investor returns.
Investors should carefully monitor any developments related to AbbVie's ongoing legal disputes or regulatory investigations, as these could have negative implications on the company's reputation and financial standing.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.
What is AbbVie's stock price target for 2024?: 13 brokers have issued 12 month price objectives for AbbVie's stock. Their ABBV share price targets range from $150.00 to $196.00. On average, they anticipate the company's share price to reach $177.43 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.
How have ABBV shares performed in 2024?: AbbVie's stock was trading at $154.97 at the beginning of the year. Since then, ABBV stock has increased by 7.2% and is now trading at $166.13.
View the best growth stocks for 2024 here.
Are investors shorting AbbVie?: AbbVie saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 13,120,000 shares, a drop of 10.7% from the March 15th total of 14,690,000 shares. Based on an average daily trading volume, of 5,660,000 shares, the days-to-cover ratio is presently 2.3 days.
View AbbVie's Short Interest.
When is AbbVie's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, April 26th 2024.
View our ABBV earnings forecast.
How can I listen to AbbVie's earnings call?: AbbVie will be holding an earnings conference call on Friday, April 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were AbbVie's earnings last quarter?: AbbVie Inc. (NYSE:ABBV) issued its earnings results on Friday, February, 2nd. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.03. The business earned $14.30 billion during the quarter, compared to the consensus estimate of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 162.28% and a net margin of 8.95%. The firm's revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $3.60 earnings per share.
Read the conference call transcript.
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?: AbbVie declared a quarterly dividend on Thursday, February 15th. Shareholders of record on Monday, April 15th will be given a dividend of $1.55 per share on Wednesday, May 15th. This represents a $6.20 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date is Friday, April 12th.
Read our dividend analysis for ABBV.

Is AbbVie a good dividend stock?: AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.81%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 50.90% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.
What ETFs hold AbbVie's stock?: ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include Harbor Health Care ETF (MEDI), First Trust Morningstar Dividend Leaders Index (FDL), Horizon Kinetics Medical ETF (MEDX), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH) and VanEck Pharmaceutical ETF (PPH).
What guidance has AbbVie issued on next quarter's earnings?: AbbVie issued an update on its FY 2024 earnings guidance on Wednesday, April, 3rd. The company provided earnings per share (EPS) guidance of 10.970-11.170 for the period, compared to the consensus estimate of 11.190. The company issued revenue guidance of -.
What is Richard A. Gonzalez's approval rating as AbbVie's CEO?: 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.
What other stocks do shareholders of AbbVie own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).
Who are AbbVie's major shareholders?: AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Guinness Asset Management LTD (0.07%), Global Assets Advisory LLC (0.05%), Ferguson Wellman Capital Management Inc. (0.04%), Miller Howard Investments Inc. NY (0.03%), Artemis Investment Management LLP (0.03%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Kevin K Buckbee, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.
How do I buy shares of AbbVie?: Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does AbbVie have any subsidiaries?: The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More

This page (NYSE:ABBV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AbbVie Stock (NYSE:ABBV)

ABBV Stock Price History

ABBV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Cons

ABBV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™